Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (40)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Grossman, E. M.
Right arrow Articles by Kaminski, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grossman, E. M.
Right arrow Articles by Kaminski, D. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 21, No. 7, 1403-1409, July 2000
© 2000 Oxford University Press

Carcinogenesis

The role of cyclooxygenase enzymes in the growth of human gall bladder cancer cells

Erik M. Grossman, Walter E. Longo, Ninder Panesar, John E. Mazuski and Donald L. Kaminski1

Department of Surgery, Saint Louis University School of Medicine, Theodore Cooper Surgical Research Institute, Grand Boulevard at Vista Avenue, PO Box 15250, St Louis, MO 63110-0250, USA

Information suggests that the cyclooxygenase (COX) metabolites, the prostanoids, play a role in gall bladder physiology and disease. Non-steroidal anti-inflammatory drugs which inhibit COX enzymes have been shown in vivo and in vitro to alter the growth patterns of intestinal epithelial cells, and specific COX-2 inhibitors have been shown to decrease mitogenesis in intestinal epithelial cells. The present study was intended to evaluate the effect of specific COX inhibitors on the growth patterns of gall bladder cancer cells. Employing a human gall bladder cancer cell line, mitogenesis, apoptosis and prostaglandin E2 (PGE2) formation were evaluated in response to serum and hepatocyte growth factor and transforming growth factor {alpha} stimulation in the presence and absence of specific COX-1 and -2 inhibitors. The effect of the mitogens on COX enzyme expression was also evaluated. Serum and the growth factors increased COX enzyme expression and mitogenesis, and decreased apoptosis as evaluated by the percentage of cells that were floating in culture media rather than attached. There was more DNA degradation in floating than in attached cells. The specific COX-2 inhibitor, but not the COX-1 inhibitor, decreased mitogenesis and increased gall bladder cell apoptosis as evaluated by the number of floating versus attached cells and the number of floating cells in the terminal phase of apoptosis or dead. The inhibition of mitogenesis and the increased apoptosis produced by the COX-2 inhibitor was associated with decreased PGE2 production. The inhibition of replication of gall bladder cancer cells and the increase in apoptosis produced by the selective COX-2 inhibitor suggests that the COX enzymes and the prostanoids may play a role in the development of gall bladder cancer and that the COX-2 inhibitors may have a therapeutic role in the prevention of gall bladder neoplasms.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
H. E. Hollingshead, M. G. Borland, A. N. Billin, T. M. Willson, F. J. Gonzalez, and J. M. Peters
Ligand activation of peroxisome proliferator-activated receptor-{beta}/{delta} (PPAR{beta}/{delta}) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms
Carcinogenesis, January 1, 2008; 29(1): 169 - 176.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Kiguchi, L. Ruffino, T. Kawamoto, E. Franco, S.-i. Kurakata, K. Fujiwara, M. Hanai, M. Rumi, and J. DiGiovanni
Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice
Mol. Cancer Ther., June 1, 2007; 6(6): 1709 - 1717.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P. Siironen, A. Ristimaki, K. Narko, S. Nordling, J. Louhimo, S. Andersson, R. Haapiainen, and C. Haglund
VEGF-C and COX-2 expression in papillary thyroid cancer.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 465 - 473.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Asano, J. Shoda, T. Ueda, T. Kawamoto, T. Todoroki, M. Shimonishi, T. Tanabe, Y. Sugimoto, A. Ichikawa, M. Mutoh, et al.
Expressions of Cyclooxygenase-2 and Prostaglandin E-Receptors in Carcinoma of the Gallbladder: Crucial Role of Arachidonate Metabolism in Tumor Growth and Progression
Clin. Cancer Res., April 1, 2002; 8(4): 1157 - 1167.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
W. Thomas, Z. K. Ascott, D. Harmey, L. W. Slice, E. Rozengurt, and A. J. Lax
Cytotoxic Necrotizing Factor from Escherichia coli Induces RhoA-Dependent Expression of the Cyclooxygenase-2 Gene
Infect. Immun., November 1, 2001; 69(11): 6839 - 6845.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.